NVision Imaging Technologies GmbH, based in Ulm, develops and sells standalone devices and consumables to improve molecular analytics, diagnostics and imaging for human and veterinary medicine, chemistry and materials science and processes the data generated by these devices. The business model is based on a quantum-physics-based technology for medical imaging; the company generates revenues from sales of hardware, consumables, software and services and pursues strategic partnerships to distribute its technology globally. In 2024 NVision launched the POLARIS platform as an MRI add-on and installed the first preclinical system at the Technical University of Munich, achieving a polarization level of 30%. NVision runs additional R&D projects in analytical magnetic resonance and quantum optics, employed on average 38 research personnel and capitalized three development projects; total R&D expenses amounted to TEUR 6,440, of which TEUR 2,556 were capitalized.
Entwicklung und Vertrieb von eigenständigen oder Zusatzgeräten zur Verbesserung der molekularen Analytik, Diagnostik und Bildgebung für die Anwendung in der Human- und Veterinärmedizin, Chemie, Materialwissenschaft sowie die Verarbeitung und Nutzung der so generierten Daten durch die genannten Geräte.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Ulm Local Court, HRB 731965 (as of 30 October 2026)
| Name | Type | City |
|---|---|---|
| Sella Brosh | Geschäftsführer(in) | Neu-Ulm |
| Ilai Schwartz | Geschäftsführer(in) | Neu-Ulm |
Source: German Commercial Register (Handelsregister) Ulm Local Court, HRB 731965 (as of 30 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | Rohergebnis€8M2 | -€3,352,000 | €31,062,203 | — |
| 2023 | Rohergebnis€5.2M2 | -€3,170,780 | €25,546,103 | — |
| 2022 | ≤ €12M1 | -€1,215,834 | €13,587,037 | — |
| 2021 | ≤ €12M1 | -€1,589,861 | €12,867,623 | — |
| 2020 | ≤ €12M1 | €69,979 | €12,463,350 | — |
| 2019 | small company1 | -€1,801,617 | €4,480,604 | — |
| 2018 | — | -€1,187,149 | €3,235,356 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Ulm Local Court, HRB 731965 (as of 30 October 2026)
Apolog Gesellschaft mit beschränkter Haftung
Quierschied · Großhandel mit medizinischen und orthopädischen Artikeln, Dental- und Laborbedarf
Klinikum Merzig gGmbH
Merzig · Krankenhäuser (ohne Hochschulkliniken, Vorsorge- und Rehabilitationskliniken)
GBA Central Lab Services GmbH
Schwentinental · Erbringung von Dienstleistungen von medizinischen Laboratorien
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €8,280,000 | 92.3% |
| Depreciation | €695,000 | 7.7% |
